25 June 2026
EMADOC-1700519818-3249573
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion[1] (post authorisation)

Ixchiq

chikungunya vaccine (live)

On 25 June 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Ixchiq. The marketing authorisation holder for this medicinal product is Valneva Austria GmbH.

The CHMP adopted a restriction to the existing indication to limit the use of Ixchiq to people aged 12 years and older who are at high risk of acquiring chikungunya infection, as follows:[2]

> Ixchiq is indicated for active immunisation for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 12 years and older **at high risk of acquiring chikungunya infection.**
>
> The use of this vaccine should be in accordance with official recommendations.

A direct healthcare professional communication (DHPC) will be disseminated on or shortly after 14 July 2026 to healthcare professionals prescribing, dispensing or administering the medicine. The DHPC will also be published on the EMA website.

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

[1] Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion.

[2] New text in bold.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union